Prevacus, Inc., a Tallahassee, FL-based early stage drug development company, received a seed funding from the Institute for the Commercialization of Public Research.
The sum of the deal, which came from the Institute’s Seed Capital Accelerator Program, and which was paired with private funding, was not disclosed.
Spun out of Florida State University in 2012, Prevacus aims to provide an effective rehabilitation for mild Traumatic Brain Injury (mTBI). Its flagship product, Prevasol Nasal Spray, utilizes Neurosteroids to improve behavioral outcomes of brain injury (working memory, sensory perception and anxiety levels) as well as enhance pro-survival molecular mechanisms after TBI (edema, apoptosis, inflammation, anti-oxidant defense, glial-immune cell infiltration).
Led by Jake Van Landingham, president, the company intends to use the capital to complete preclinical proof of concept studies, develop a drug safety profile and enter into large animal toxicology studies. All important activities will be completed for entry into Phase I/II clinical trials in the coming year.